Found: 7
Select item for more details and to access through your institution.
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2021.804988
- By:
- Publication type:
- Article
A Maturation Index defines Newly Diagnosed Multiple Myeloma Patients with advanced immunophenotypic and Molecular Differentiation profiles associated with poor prognosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e69, doi. 10.1016/j.clml.2019.09.110
- By:
- Publication type:
- Article
A More Mature Immunophenotypic Make-up of Multiple Myeloma Clone(s) at Diagnosis Correlates With a Higher Genomic Instability.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e11, doi. 10.1016/j.clml.2017.03.019
- By:
- Publication type:
- Article
Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody.
- Published in:
- European Journal of Haematology, 2008, v. 80, n. 4, p. 322, doi. 10.1111/j.1600-0609.2007.01015.x
- By:
- Publication type:
- Article
Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia.
- Published in:
- Cancers, 2019, v. 11, n. 11, p. 1654, doi. 10.3390/cancers11111654
- By:
- Publication type:
- Article
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 4, p. 734, doi. 10.1002/hon.3029
- By:
- Publication type:
- Article
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 580, doi. 10.1002/hon.2886
- By:
- Publication type:
- Article